Biden signs bill limiting new drug exclusivity awards to innovations in active moiety

Published date27 April 2021
Subject MatterFDA,Life Sciences,FDCA,Prescription Drugs,Biosimilars,New Legislation,Regulatory Reform,Product Exclusivity,Pharmaceutical Industry
AuthorDavid Fox,George O'Brien,Jason Conaty
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT